Skip to content
Boost Up Blog – Lifestyle
Author:
Silexion Therapeutics Corp
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
August 4, 2026
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
July 29, 2026
Silexion Therapeutics Receives Approval from Germany’s BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
June 23, 2026
Silexion Therapeutics to Attend BIO International Convention 2026
June 16, 2026
Columbus McKinnon Delivers Order Growth of 20% and Net Sales Growth of 24% in FY26; Issues FY27 Guidance
June 4, 2026
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
May 26, 2026
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 21, 2026
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds
May 21, 2026
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer
May 21, 2026
1
2
Next Page
→